ID: MRFR/Pharma/1984-HCR | February 2021 | Region: Middle East & Africa | 84 pages
Market Synopsis of Middle East and Africa Human Vaccines Market:
A vaccine is a biological preparation which contains a weakened or killed microbial agent, its toxins or its surface proteins, which provides active acquired immunity against the disease caused by the microbe.
The aim of vaccination is to stimulate and train the body immunity to recognize and destroy the microbial threat in later encounters. Vaccination is the most effective method of preventing infectious diseases and is largely responsible for eradicating many deadly diseases such as smallpox and the restriction of diseases such as measles, and tetanus.
Middle East and Africa are laggards when it comes to immunization coverage. According to World Health Organization (WHO), out of the total number of children worldwide who did not receive the required three doses of diphtheria-tetanus-pertussis vaccines, more than 40% were from sub-Saharan Africa. Other nations with large unvaccinated population include Nigeria, Iraq, Chad, Niger, Angola, Somalia and Sudan. UNICEF estimates that in 2015, Central African Republic, Equatorial Guinea, Somalia, South Sudan, Syrian Arab Republic and Ukraine had less than 50%coverage of the third dose of diphtheria, tetanus and pertussis (DTP) vaccine. More than half of the unvaccinated children live in Democratic Republic of Congo, Ethiopia, India, Indonesia, Iraq, Nigeria, Pakistan, Philippines, Uganda and South Africa.
Thus Middle East and Africa offer immense potential and opportunities for the vaccine market. Apart from the unmet needs for vaccination, second most important market driving factor are the policies of national Governments and international bodies such as World health organization (WHO). For example vaccine action plan of WHO along with huge funding from international bodies were responsible for driving the vaccine market to great heights in the past and also resulted in development and expansion of vaccine production capacities especially in developing states notably India. Other driving factors are increasing funds from philanthropy organizations such as Bill and Melinda Gates foundation, inclusion of several new vaccines in the national immunization schedule of many countries, development of new vaccines which includes vaccine for hepatitis, growing awareness of vaccination, growth of manufacturing low cost vaccines especially in developing countries, the entry of China in the vaccine market etc.
The market’s constraints include falling profitability of vaccine, manufacturing, eradication of diseases such as smallpox which effectively eliminates the need for vaccine, side effects associated with vaccines, variability of efficacy of vaccines and difficulty of producing vaccines for microbes with high mutations such as HIV.
The low profitability in vaccine manufacturing has reduced incentives for developing vaccines for diseases of the developing world such as tuberculosis and malaria.
The market’s trends include strong research pipeline under which number of novel vaccines are being developed such as rubella vaccine, ebola vaccine etc. DNA recombinant technology is also a common technology used in the development of novel acting vaccines.
Taking all the factors into consideration, we expect the Middle East and Africa human vaccines market which was $ 2.8 billion in 2015 to reach around $ 5.46 billion in future, growing at a CAGR of 11.8%.
Study Objectives Middle East and Africa Human Vaccines Market:
Middle East and Africa Human Vaccines Market, by Technology, 2015 (%)
Key Players for Middle East and Africa Human Vaccines Market:
Some of the key players in this market are GlaxoSmithKline Plc., Merck & Co. Inc., Pfizer, Inc., Sanofi Pasteur, Inc., AstraZeneca Plc., Bharat Biotech, Shenzhen Kangtai Biological Products, Valeant Pharmaceuticals, Emergent Biosolutions Inc., Astellas Pharma Inc., Panacea Biotec and others.
Middle East and Africa human vaccines market has been segmented on the basis of technology which comprises attenuated, inactivated, toxoid, conjugate & subunit, recombinant DNA. On the basis of disease indication; market is segmented into pneumococcal, influenza, hepatitis, rotavirus, DTP, polio and others. On the basis of type the market is segmented into prophylactic and therapeutic. On the basis of composition market is again segmented into mono vaccine and combination vaccines. The route of administration segments the market into oral, injectable and other. Moreover on the basis of end user; market is segmented into children and adults.
Regional Analysis of Middle East and Africa Human Vaccines Market:
Depending on geographic region, human vaccine market is segmented into several countries: UAE is the largest market for human vaccines in the entire Middle East and Africa human vaccines market closely followed by Egypt. The rest of Africa’s market especially Sub Saharan regions are however the fastest growing market with a huge unmet medical needs.
Frequently Asked Questions (FAQ) :
Middle East and Africa Human Vaccines Market is projected to grow at an 11.8% CAGR between 2014-2022.
Middle East and Africa Human Vaccines Market is predicted to touch USD 5.46 billion by 2022.
UAE is predicted to dominate the Middle East and Africa Human Vaccines Market.
Unmet vaccination needs and development of new vaccines are adding market growth.
Side effects may limit market growth.
Table of Content
1.2 Scope of Study
1.3 Research Objective
1.4 Assumptions & Limitations
1.5 Market Structure:
2 Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
3 Market Dynamics
3.5 Macroeconomic Indicators
4 Market Factor Analysis
4.1 Porter’s Five Forces Model
4.1.1 Bargaining Power of suppliers
4.1.2 Bargaining Power of Customer
4.1.3 Intensity of Competitor’s
4.1.4 Threat of New Entrants
5 Middle East and Africa Human Vaccines Market, by Technology
5.1.4 Conjugate and Subunit
5.1.5 Recombinant DNA
6 Middle East and Africa Human Vaccines Market, by Disease Indication
7 Middle East and Africa Human Vaccines Market, by Type
8 Middle East and Africa Human Vaccines Market, by Composition
8.1.1 Mono vaccine and
8.1.2 Combination vaccines
9 Middle East and Africa Human Vaccines Market, by Route of Administration
10 Middle East and Africa Human Vaccines Market, by End User
11 Middle East and Africa Human Vaccines Market, by Country
11. 1.3 Egypt
11. 1.4 Saudi Arabia
11. 1.5 Kuwait
11. 1.6 Qatar
11. 1.7 Oman
12 Company Landscape
12.1.1 Mergers Acquisitions
12.1.3 Release/New Product Launches
12.1.4 Other (Expansion, Updates, Partnership)
13 Company Profile
13.1 GlaxoSmithKline Plc.
13.1.1 Company Overview
13.1.2 Product/Business Segment Overview
13.1.4 Key Developments
13.1.5 SWOT Analysis
13.2 Merck & Co. Inc.
13.2.2 Product/Business Segment Overview
13.2.4 Key Developments
13.2.5 SWOT Analysis
13.3 Pfizer, Inc.
13.3.2 Product/Business Segment Overview
13.3.4 Key Developments
13.3.5 SWOT Analysis
13.4 Sanofi Pasteur, Inc.
13.4.2 Product/Business Segment Overview
13.4.4 Key Developments
13.4.5 SWOT Analysis
13.5 AstraZeneca Plc.
13.5.2 Product/Business Segment Overview
13.5.4 Key Developments
13.5.5 SWOT Analysis
13.6 Bharat Biotech
13.6.2 Product/Business Segment Overview
13.6.4 Key Developments
13.6.5 SWOT Analysis
13.7 Shenzhen Kangtai Biological Products
13.7.2 Product/Business Segment Overview
13.7.4 Key Developments
13.7.5 SWOT Analysis
13.8 Valeant Pharmaceuticals
13.8.2 Product/Business Segment Overview
13.8.4 Key Developments
13.8.5 SWOT Analysis
13.9 Emergent Biosolutions Inc.
13.9.2 Product/Business Segment Overview
13.9.4 Key Developments
13.9.5 SWOT Analysis
13.10 Astellas Pharma Inc.
13.10.2 Product/Business Segment Overview
13.10.4 Key Developments
13.10.5 SWOT Analysis
13.11 Panacea Biotec
13.11.2 Product/Business Segment Overview
13.11.4 Key Developments
13.11.5 SWOT Analysis
List of Tables
TABLE 1 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, 2013-2022 (USD MILLION)
TABLE 2 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY TECHNOLOGY, 2013-2022 (USD MILLION)
TABLE 3 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2013-2022 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY TYPE, 2013-2022 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY COMPOSITION, 2013-2022 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2013-2022 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY END USER, 2013-2022 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY REGION, 2013-2022 (USD MILLION)
List of Figures
FIGURE 1 RESEARCH PROCESS
FIGURE 2 PORTERS FIVE FORCES MODEL
FIGURE 3 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY TECHNOLOGY
FIGURE 4 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY DISEASE INDICATION
FIGURE 5 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY TYPE
FIGURE 6 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY COMPOSITION
FIGURE 7 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY ROUTE OF ADMINISTRATION
FIGURE 8 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY END USER
FIGURE 9 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY REGION
FIGURE 10 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET: COMPANY SHARE ANALYSIS, 2015 (%)